Valuation: AbbVie Inc.

Market Cap 438B 383B 354B 327B 616B 42,087B 627B 4,221B 1,656B 20,609B 1,646B 1,609B 70,961B P/E 2026 *
30.7x
P/E 2027 * 23.3x
Enterprise Value 495B 432B 400B 369B 695B 47,504B 708B 4,765B 1,869B 23,261B 1,858B 1,817B 80,093B EV / Sales 2026 *
7.36x
EV / Sales 2027 * 6.68x
Free-Float
95.71%
Yield 2026 *
2.77%
Yield 2027 * 2.92%
1 day-1.01%
1 week-3.80%
Current month-2.57%
1 month+10.30%
3 months+15.95%
6 months+9.28%
Current year+5.43%
1 week 34.16
Extreme 34.16
35.52
1 month 29.71
Extreme 29.71
37
Current year 26.89
Extreme 26.89
37
1 year 26.36
Extreme 26.36
37
3 years 19.83
Extreme 19.83
37
5 years 19.45
Extreme 19.45
37
10 years 19.45
Extreme 19.45
37
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.01%-3.80% - - 438B
-2.48%-6.72%+44.19%+156.43% 1,054B
-1.52%-5.01%+61.87%+58.79% 621B
-1.12%-1.45%+27.34%+22.20% 325B
-1.73%-2.14%+27.22%+44.70% 281B
-1.95%-13.92%+15.96%+19.76% 262B
-1.45%-0.44%-27.17%-38.86% 219B
-1.44%-3.49%+19.60%+56.20% 195B
-1.04%-4.63%+16.01%+68.47% 163B
-0.94%+0.75%-4.34%-33.23% 140B
Average -1.37%-1.05%+20.08%+39.38% 361.95B
Weighted average by Cap. -1.35%-1.35%+32.39%+72.21%

Financials

2026 *2027 *
Net sales 67.23B 58.76B 54.32B 50.18B 94.5B 6,458B 96.21B 648B 254B 3,162B 253B 247B 10,889B 72.79B 63.61B 58.8B 54.33B 102B 6,992B 104B 701B 275B 3,424B 273B 267B 11,788B
Net income 14.58B 12.74B 11.78B 10.88B 20.49B 1,400B 20.86B 140B 55.11B 686B 54.76B 53.55B 2,361B 19B 16.6B 15.35B 14.18B 26.7B 1,825B 27.18B 183B 71.81B 894B 71.36B 69.78B 3,077B
Net Debt 56.39B 49.28B 45.55B 42.09B 79.26B 5,416B 80.69B 543B 213B 2,652B 212B 207B 9,132B 47.87B 41.84B 38.68B 35.73B 67.29B 4,599B 68.51B 461B 181B 2,252B 180B 176B 7,753B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-07-14 $34.16 -1.01% 971
26-07-13 $34.51 -0.32% 3,433
26-07-10 $34.62 -0.37% 1,116
26-07-09 $34.75 -1.95% 2,043
26-07-08 $35.44 -0.20% 3,609
Trader
Investor
Global
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
248.00USD
Average target price
265.50USD
Spread / Average Target
+7.06%

Quarterly revenue - Rate of surprise